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Editorial Comment
Multivessel Balloon Angioplasty
Should Be Abandoned in
Diabetic Patients!*
WILLIAM W. O’NEILL, MD, FACC
Royal Oak, Michigan
Revascularization decision. When we as clinicians sit with
a patient and their family to advise them about revasculariza-
tion, an enormous professional and ethical obligation is placed
on our shoulders. Patients literally and figuratively place their
lives in our hands. Often at the end of a long complex
discussion about outcomes, risks, benefits and costs, a patient
will look straight into your soul and say, “I’ll do whatever you
say.” Or, equally pointedly, “If I was your (mother/father/
brother), what would you advise?” Experienced clinicians
recognize that the choice of revascularization procedures is
unique to each patient. A myriad of social, economic, medical
and, finally, technical factors enter into our synthesis for an
ultimate recommendation. Because patients and society have
placed this enormous responsibility on us, it is imperative that
we become well armed with as much information as possible to
assist our patients in making an informed decision that is right
for them. This information must include an in-depth knowl-
edge of the patient’s personal expectations and family needs
and resources. Of course, a detailed knowledge about the
disease process and an estimate of individual long-term prog-
nosis are necessary. It is also necessary to include detailed,
objective technical proficiency data about the surgical or
interventional program to which the patient is referred. Fi-
nally, we must ensure that self-referral bias does not enter this
equation.
After discussing personal needs and expectations, patients
are intently interested in technical details. Will it hurt? How
long will I be in the hospital? How long will it take to recover?
When can I return to work? These patient comfort questions
have tended to favor balloon angioplasty over bypass surgery in
the past. An important, previously unanswerable, question was,
“Which treatment will allow me to live longer?”
To this end, Weintraub et al. (1) in this issue of the Journal
attempt to provide long-term outcome information for diabetic
patients with multivessel disease undergoing revascularization
at Emory University Hospital from 1981 to 1994. Because
diabetic patients comprise 20% to 30% of interventional
practices, the unique characteristics of this patient population
are critically important to understand. The authors conclude
that diabetic patients treated with angioplasty had less exten-
sive disease, slightly better ventricular function and no differ-
ence in unadjusted long-term survival. Although at first glance
this analysis is reassuring, a more detailed analysis suggests
that when risk adjustment for baseline variables occurs, dia-
betic patients fare better with bypass surgery than with angio-
plasty. Given these unexpected findings, should a moratorium
be placed on percutaneous intervention in diabetic patients?
Diabetes mellitus is a potent risk factor for the development
of coronary artery disease and independently worsens long-
term prognosis for medically treated patients (2–4). The
mechanism for hyperglycemia and hyperinsulinemia to accel-
erate development and progression of coronary artery disease
is multifactorial. Endothelial dysfunction, enhanced platelet
activation, enhanced prothrombotic activity and enhanced
growth factor production can all contribute to rapid disease
progression. These same factors may explain the proclivity for
restenosis that is apparent after coronary angioplasty.
Outcome after bypass surgery. Before rushing all our
patients off to bypass surgery, it must be understood that
diabetes also adversely affects short- and long-term outcome
after coronary bypass. In the Emory experience, the in-hospital
mortality rate was 5% in bypass group patients compared with
0.36% in coronary angioplasty group patients. In the Bypass
Angioplasty Revascularization Investigation (BARI) (5), the
mortality rate was double (1.2% vs. 0.6%) for surgically treated
patients with diabetes. Herlitz et al. (6) has demonstrated that
initial and 2-year survival were significantly worse for diabetic
patients operated on in Goteborg, Sweden. Diabetic patients
have more diffuse atherosclerosis, making grafting less success-
ful. Patients with adult-onset diabetes often tend to be obese.
Diabetes affects wound healing and predisposes to postopera-
tive infections. All these factors make surgeons cautious about
operating on diabetic patients. Finally, the BARI study itself
has again demonstrated that surgically treated diabetic pa-
tients have a worse 5-year survival probability than nondiabetic
patients (80.6% vs. 91.4%).
Outcome after angioplasty. When balloon angioplasty was
first developed, patient selection was confined to patients with
single-vessel disease; isolated, concentric, noncalcified lesions;
and normal ventricles. In these types of patients, prognosis was
excellent, irrespective of therapy. Now that percutaneous
intervention has broadened to include complex diffuse disease,
multivessel disease, unstable angina and acute myocardial
infarction, it is likely that subgroups with an improved or
worsened prognosis may be identified. One such subgroup is
insulin-treated diabetic patients. The National Heart, Lung,
and Blood Institute (NHLBI)-I registry (7) found no difference
in hospital outcome for diabetic patients. As more complex
disease was tackled in the NHLBI-II (8) registry, diabetic
patients had a worse in-hospital mortality rate (3.2% vs. 0.5%).
More recently, the Emory experience has found that as tech-
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nique has improved, mortality is the same for patients with and
without diabetes (,0.4%). At the present time, diabetes does
not appear to worsen the immediate outcome for percutaneous
coronary intervention.
Unfortunately, the long-term outcome does appear to be
dramatically impacted. Because immediate outcome and major
cardiac events are not elevated in diabetic patients, the adverse
outcome must be related to disease progression and restenosis.
The hyperglycemia and hyperinsulinemia that promote athero-
sclerosis progression also dramatically enhance restenosis.
Hyperglycemia causes endothelial dysfunction by decreasing
endothelium-derived relaxing factor production (9), increasing
free radical formation (10) and decreasing prostocyclin pro-
duction (11). At the same time, platelet hyperaggregability
occurs. Enhanced thromboxane A2 production (12) and in-
creased Factor VII (13) and anti-thrombin III (14) production
occur. These factors predispose vessels to coronary thrombo-
sis. Van Belle et al. (15) have in fact demonstrated that late
vessel occlusion occurs in 14% of diabetic versus 3% of
nondiabetic patients treated with coronary angioplasty.
Although hyperglycemia promotes thrombosis, hyperinsu-
linemia is a potent mitogen for restenosis. Platelet-derived
growth factor and insulin-like growth factor are elevated in
diabetic patients and may promote smooth muscle cell trans-
formation (16). Strict glycemic control may downregulate these
prothrombotic and prorestenotic factors. Aronson et al. (17)
have elegantly made the argument for a clinical trial of strict
diabetic control in diabetic patients treated with angioplasty.
In the context of the known predilection for thrombosis and
restenosis to occur in diabetic patients, the worsened long-term
outcome for these patients is understandable. Holmes et al. (7)
first reported that diabetic patients had a higher restenosis rate
in the NHLBI-I registry (47% vs. 32%). Kip et al. (8) found
major adverse consequences in diabetic patients in the
NHLBI-II registry. They reported a 9-year mortality rate of
35.9% versus 17.9% and 9-year rates of myocardial infarction
of 29% versus 18% for diabetic and nondiabetic patients,
respectively. Stein et al. (18) similarly reported on the Emory
experience and found a 36% versus 53% 5-year event-free
survival rate for diabetic versus nondiabetic patients. In fact,
the 5-year survival rate was significantly lower (88% vs. 93%,
p , 0.0001) for diabetic patients. Finally, the BARI trial found
that the 5-year survival rate after diabetes was lower (65.5% vs.
91.4%) for diabetic patients.
The high rate of restenosis and late occlusion is difficult to
diagnose because of the known tendency for diabetic patients
to present with silent ischemia. Because ventricular function,
extent of disease and angioplasty results are the same in
diabetic patients, the worse long-term survival can only be
explained by late coronary occlusion causing fatal myocardial
infarction or restenosis causing ischemia and predisposing to
lethal arrhythmias.
Outcome after stent implantation. The advent of wide-
spread coronary stenting has dramatically altered interven-
tional cardiology practice. Whether the improved restenosis
rates reported in the randomized trials also occur in diabetic
patients remains controversial. Van Belle et al. (15) have
carefully studied two large groups of patients treated with
coronary angioplasty or single-stent implantation. They re-
ported similar rates of restenosis and late loss in diabetic and
nondiabetic patients undergoing stenting.
Conversely, Kornowski et al. (19) have reported similar
elevated rates of fibrointimal hyperplasia in diabetic patients
with stenting. This finding has translated into enhanced rates
of target lesion revascularization at the Washington Heart
Center. Tilli et al. (20) reported on the William Beaumont
Hospital experience and also found higher rates of target
lesion revascularization in diabetic patients. Finally, Carozza et
al. (21) demonstrated enhanced late loss in diabetic stent-
treated patients at Beth Israel Hospital. All these studies are
retrospective and have multiple confounding variables, such as
different anticoagulation regimes, different stent deployment
techniques and different numbers of stents deployed. Suffice it
to say that the same propensity for restenosis that occurs after
balloon angioplasty may still be a problem after stent implan-
tation.
Call to arms. Are these data sufficiently compelling to
warrant abandonment of balloon angioplasty in diabetic pa-
tients? Given the disturbing mortality results from the BARI
trial and the present report by Weintraub et al. (1), and given
the exorbitant rates of restenosis and the major events re-
ported by Van Belle et al. (15) and Stein et al. (18), I believe
that this therapy, as practiced (circa 1990), should be aban-
doned. After all, balloon aortic valvuloplasty was abandoned as
an alternative to valve replacement when restenosis rates of
60% to 80% were reported (22). Multilesion balloon angio-
plasty in treated diabetic patients approaches these numbers.
However, we may not do our patients justice by subjecting
them to the increased procedural risks of coronary bypass
surgery.
Hopefully, this commentary will serve as a call to arms (or
needles) to my interventional colleagues. The unacceptably
high rates of restenosis after balloon angioplasty in diabetic
patients simply can no longer be overlooked and accepted.
Rather than abandoning percutaneous intervention in these
patients, what should be done? 1) It is apparent that rigid
glycemic control must be studied. This therapy requires active
collaboration with our endocrinology colleagues and should be
tested after coronary bypass as well. 2) Aggressive adjunctive
pharmacologic therapy with angiotensin-converting enzyme
inhibitors, hypocholesteremic agents and oral glycoprotein
receptor blocking agents is required. 3) The extent to which
stent therapy has limited the stent restenosis/thrombosis risk in
diabetic patients needs more careful prospective evaluation. In
this regard, the cardiology community must actively support
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the efforts of replicating the BARI trial with modern revascu-
larization techniques in diabetic patients. At the present time,
if we recommend multivessel percutaneous intervention to our
diabetic patients, aggressive risk factor modification, tight
glycemic control and intensive routine noninvasive screening
for asymptomatic restenosis must occur.
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